Harmony Biosciences Holdings
$ 38.41
-0.88%
07 Aug - close price
- Market Cap 2,236,860,000 USD
- Current Price $ 38.41
- High / Low $ 39.43 / 38.20
- Stock P/E 12.51
- Book Value 17.19
- EPS 3.07
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.12 %
- ROE 0.20 %
- 52 Week High 40.87
- 52 Week Low 25.52
About
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Analyst Target Price
$46.10
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-07 | 2026-02-24 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-10-29 | 2024-08-06 | 2024-04-30 | 2024-02-22 | 2023-10-31 |
| Reported EPS | 1.28 | 0.79 | 0.57 | 1.08 | 0.92 | 0.7785 | 1.08 | 1.03 | 1.05 | 0.88 | 0.45 | 0.97 |
| Estimated EPS | 0.97 | 0.93 | 0.86 | 0.86 | 0.96 | 0.9136 | 0.82 | 0.88 | 0.12 | 0.69 | 0.48 | 0.81 |
| Surprise | 0.31 | -0.14 | -0.29 | 0.22 | -0.04 | -0.1351 | 0.26 | 0.15 | 0.93 | 0.19 | -0.03 | 0.16 |
| Surprise Percentage | 31.9588% | -15.0538% | -33.7209% | 25.5814% | -4.1667% | -14.7877% | 31.7073% | 17.0455% | 775% | 27.5362% | -6.25% | 19.7531% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HRMY
2026-08-06 16:12:52
Harmony Biosciences will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. A webcast of the event will be available on the investor page of the company's website. Harmony Biosciences focuses on developing innovative therapies for rare neurological diseases.
2026-08-06 12:12:52
Harmony Biosciences (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. A live webcast will be accessible via the investor page of the Harmony Biosciences website. The company is focused on developing and commercializing therapies for patients with rare neurological diseases.
2026-08-05 17:41:25
Two healthcare stocks, Harmony Biosciences Holdings (HRMY) and Beam Therapeutics (BEAM), have received bullish ratings from analysts. H.C. Wainwright reiterated a Buy rating for Harmony Biosciences with a $55.00 price target, while Beam Therapeutics holds a Strong Buy consensus with a target of $55.00, suggesting significant upside. These recommendations highlight analyst confidence in the future performance of these companies within the healthcare sector.
2026-08-05 03:41:25
Harmony Biosciences Holdings, Inc. reported strong second-quarter 2026 results, with revenue reaching $261.28 million and diluted EPS at $1.28, significantly up from the prior year. This growth was driven by increased product volume and a price adjustment in January 2026. The company also highlighted expanded formulary coverage, progress in its product pipeline with an NDA submitted for Pitolisant GR, and active IP and licensing efforts.
2026-08-04 21:46:00
Harmony Biosciences Holdings, Inc. reported record Q2 2026 net revenue of $261.3 million for WAKIX, a 30% year-over-year increase, and reaffirmed full-year guidance of $1 billion to $1.04 billion. The company highlighted promising Phase I data for its new orexin-2 receptor agonist, BP-205, with multiple catalysts expected, and detailed its strategic financial position with $962.5 million in cash for potential M&A. Operational challenges include increased cost of sales due to new royalty obligations and ongoing litigation with an ANDA filer, AET Pharma.
2026-08-04 20:10:56
Oppenheimer analyst Andreas Argyrides has lowered the price target for Harmony Biosciences Holdings Inc. (HRMY) to $70. This information was updated on August 4, 2026, at 2:30 PM EDT. The full details of this analyst action are available only to premium subscribers of StreetInsider.com.
